Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Prostate-specific antigen (PSA) in combination with digital rectal examination forms the basis for current prostate cancer (CaP) screening programs. Although PSA screening was recently shown to reduce CaP-specific mortality in the European randomized trial, its limitations include the risk for unnecessary prostate biopsy and the diagnosis and treatment of some CaP that might never have caused suffering or death. A potential way to minimize these pitfalls is through the use of derivatives of PSA, particularly PSA kinetics, to increase the specificity for clinically relevant CaP. CaP is the second-leading cause of cancer death in men in the United States and many other westernized countries; accordingly, judicious screening of healthy men allows for diagnosis sufficiently early that all options (i.e., treatment or surveillance) are still available in most cases.

Original languageEnglish (US)
Pages (from-to)265-270
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume8
Issue number2
DOIs
StatePublished - Feb 2010

Keywords

  • Kinetics
  • PSA
  • Prostate cancer
  • Screening
  • Threshold

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values'. Together they form a unique fingerprint.

  • Cite this